AR and prostate carcinoma: To determine the impact of VT-464 on AR signaling, we measured the effects of VT-464 on a AR reporter construct, FKBP51-ARE-luciferase, which is activated in the presence of the synthetic androgen 1nM R1881 in C4-2B prostate cancer cells (Fig. 5A).